Floyd Petersen Sells 500 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 500 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $25.27, for a total value of $12,635.00. Following the transaction, the director owned 75,531 shares in the company, valued at $1,908,668.37. This trade represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amphastar Pharmaceuticals Trading Up 0.2%

AMPH traded up $0.05 during midday trading on Wednesday, hitting $25.31. The company’s stock had a trading volume of 335,114 shares, compared to its average volume of 537,416. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.39 and a 52-week high of $53.96. The firm has a 50-day moving average price of $26.59 and a two-hundred day moving average price of $25.27. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm has a market cap of $1.18 billion, a P/E ratio of 9.48 and a beta of 0.75.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AMPH. Bank of America upped their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Zacks Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target on shares of Amphastar Pharmaceuticals in a research report on Wednesday, October 22nd. Finally, Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $31.60.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in shares of Amphastar Pharmaceuticals by 46.6% during the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after purchasing an additional 424 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 14.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company’s stock worth $400,000 after buying an additional 1,694 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Amphastar Pharmaceuticals by 9.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company’s stock worth $434,000 after buying an additional 1,262 shares during the period. Principal Financial Group Inc. lifted its holdings in Amphastar Pharmaceuticals by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 212,647 shares of the company’s stock worth $6,165,000 after buying an additional 4,669 shares in the last quarter. Finally, Significant Wealth Partners LLC boosted its position in Amphastar Pharmaceuticals by 43.2% in the 1st quarter. Significant Wealth Partners LLC now owns 10,215 shares of the company’s stock valued at $296,000 after buying an additional 3,080 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.